Tossed in a storm of controversies, Proteostasis finds shelter in $100M cash Roche deal — shares surge
After a tumultuous year marked by a vicious short attack, a yanked stock offering and encouraging early data on its cystic fibrosis …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
